Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Depomed (NASDAQ: DEPO) today and set a price target of $9. The company’s shares opened today at $8.21.
Rivkind Koffler wrote:
“We note that each $100M up or down from our current assumptions represents ~$2/share in valuation.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 13.1% and a 48.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Pacira Pharmaceuticals, and Adamas Pharmaceuticals.
Depomed has an analyst consensus of Moderate Buy, with a price target consensus of $9.50, implying a 15.7% upside from current levels. In a report released yesterday, Janney Montgomery also upgraded the stock to Buy with a $10 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.15 and a one-year low of $4.31. Currently, Depomed has an average volume of 1.45M.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Depomed, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.
